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gression analysis are the number of days of heparin use
and the intensity of diagnostic follow-up, as expressed by
the number of VQ-scans. CONCLUSIONS: The manage-
ment of PE, from suspicion until discharge, is rather con-
sistent; however, large inter-individual variation in hospital
stay is observed. Interestingly, the length of hospitaliza-
tion is related to the duration of heparin use. This perhaps
opens perspectives for anticoagulation that can be ad-
ministered ambulatory. A patient chart review has the
advantage over database research that only resource use
strictly related to the investigated condition can be identified.
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OBJECTIVE: To determine pharmacoeconomically opti-
mal hypolipidemic drug for preventive maintenance of
CAD in women of elder age groups. METHODS: 110
women, average age 59  3,4 yrs., with menopause du-
ration more than 5 years, hypercholesterolemia types IIA
and IIB, coronary heart disease, angina pectoris of II–III
functional class without clinical signs of heart insuffi-
ciency were included into the study. They were divided
into 5 groups by a method of envelopes: patients of I
group received simvastatinin - 10–20 mg o.d., patients of
II group - fluvastatin 40–80 mg o.d., patients of III group -
pravastatin 20–40 mg o.d., IV group - fenofibrate 200
mg o.d., V group-ciprofibrate - 100 mg o.d. Statins were
initially given in bioequivalent doses. The groups of ther-
apy were completely comparable to age; duration of dis-
ease and character of accompanying therapy, and also by
levels TC and LDL-C Therapy duration was 12 weeks.
After 4 and 12 weeks the levels of TC, LDL-C, HDL-C,
TG and also conventional biochemical criterion of safety
of therapy were determined. The criterion of cost-effec-
tiveness for each drug was defined under the following
formula, permitting to determine the cost of 1% reduc-
tion of LDL-C by various hypolipidemic drugs: Ñ-E 
(DMC  FC)/% of LDL-C reduction, where DMC—the
direct medical costs including cost of a medical reception
and cost of an out-patient inspection according to the
standards of the prices for medical services in adult out-
patient departments of Moscow under the program of
voluntary medical insurance in 1997–98; FC-cost of a
monthly course of treatment by different drugs in Mos-
cow chemist’s web in 1997–98. CONCLUSION: The
comparison of hypolipidemic drugs by a criterion “cost-
effectiveness”, using as a criterion of therapy efficiency
percentage of LDL-C reduction, arranged the drugs as
follows: ciprofibrate (100 mg) - fluvastatin (40 mg) - sim-
vastatin (10 mg) - fenofibrate (200mg) - fluvastatin (80mg) -
simvastatin (20mg) - pravastatin (20 mg) - pravastatin
(40 mg).
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OBJECTIVE: To examine the variation in total costs of
treating patients with hypercholesterolemia to achieve
EAS LDL-C target concentration levels using statins.
METHODS: A randomized, 54-week, controlled trial
was conducted to compare resources used when treating
patients to EAS LDL-C targets using atorvastatin, fluva-
statin, pravastatin and simvastatin. Variation in total
costs among the arms of the study could be attributed to
the time at which patients achieved LDL-C targets and
the services and medications required to reach LDL-C
target. Costs include costs of study drug, add-on therapy,
physician office visits, lab tests and attributable adverse
events. RESULTS: There was substantial variation in to-
tal costs and in the components of total costs among
study arms. Patients treated with atorvastatin achieved
LDL-C target significantly faster (P  0.05) at lower
doses of study drug and required significantly fewer clinic
visits than patients treated with comparator statins. Con-
sequently, mean total cost of care to reach LDL-C targets
were significantly lower than costs for patients treated
with comparators (P  0.05). CONCLUSION: Costs for
treating patients to LDL-C targets with HMG-CoA re-
ductase inhibitors varied significantly among drugs. To-
tal costs of therapy were lowest with atorvastatin, when
compared to other reductase inhibitors examined in this
study.
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OBJECTIVE: To examine the variation in total costs of
treating patients according to EAS LDL-C target concen-
tration levels attributable to use of alternative HMG-
CoA reductase inhibitors (statins). METHODS: A ran-
domized, 54-week, controlled trial was conducted to
compare resources used when treating patients to EAS
LDL-C targets using atorvastatin, fluvastatin, pravastatin
and simvastatin. The trial enrolled 336 patients. Patients
were dispensed study drugs according to the protocol;
starting at the lowest dose and titrating up at regular in-
tervals if LDL-C targets were not met. Per the protocol,
the amount of resources consumed varied based upon the
time at which patients achieved LDL-C targets. In this
treat-to-target study, it was possible to achieve target in
